Sab Biotherapeutics, INC 8-K filings

SAB Biotherapeutics announced a grant from Breakthrough T1D to support a clinical study evaluating SAB-142 in patients with Stage 3 Type 1 Diabetes.

SAB Biotherapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of four Class II directors and the ratification of its independent auditor.

SAB Biotherapeutics has entered into a Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. for its SAB-142 product.

SAB Biotherapeutics announced positive Phase 1 trial data for SAB-142, showing C-peptide preservation and improved glycemic control in Type 1 Diabetes patients.

SAB Biotherapeutics provides a corporate update, highlighting positive Phase 1 data for SAB-142, initiation of its registrational Phase 2b SAFEGUARD study, and a cash runway through 2028.

SAB Biotherapeutics appoints Dr. David Zaccardelli as Board Chair and Dr. Rita Jain as an independent director, enhancing leadership for clinical development.

SAB Biotherapeutics, Inc. announced the establishment of a new at-the-market offering program to sell up to $75 million in common stock, replacing a prior $20 million program.

SAB Biotherapeutics announced the resignations of two directors and a reduction in its board size from 11 to nine members, effective September 30, 2025.

SAB Biotherapeutics stockholders approved a significant increase in its equity incentive plan shares and the potential conversion of Series B Preferred Stock, which could exceed 19.99% of outstanding common stock.

SAB Biotherapeutics, Inc. announced an oversubscribed $175 million private placement, including strategic investor Sanofi, to fully fund its pivotal Phase 2b SAFEGUARD study for SAB-142 in Type 1 Diabetes and extend its cash runway into mid-2028.

SAB Biotherapeutics, Inc. announced the successful re-election of its Class I directors and the ratification of EisnerAmper LLP as its independent auditor during its 2025 Annual Meeting of Stockholders.

SAB Biotherapeutics secures a five-year lease for office and research space in Sioux Falls, South Dakota, committing to an annual rent of $601,630.82.

SAB Biotherapeutics reports positive topline Phase 1 clinical trial results for SAB-142, a potential disease-modifying therapy for type 1 diabetes, showing a favorable safety profile and strong pharmacodynamic activity.

SAB Biotherapeutics announced progress in its Phase 1 clinical trial for SAB-142, a novel immunotherapy for type 1 diabetes, highlighting the completion of healthy volunteer enrollment and the absence of serum sickness.

SAB Biotherapeutics has appointed Lucy To as its new Chief Financial Officer, effective August 12, 2024.

SAB Biotherapeutics held its 2024 Annual Meeting, where shareholders elected three directors, approved an amendment to the equity incentive plan, and ratified the appointment of its accounting firm.

SAB Biotherapeutics has appointed Mark Conley as Interim Chief Financial Officer, effective June 4, 2024, following the resignation of Michael King.

SAB Biotherapeutics has received FDA clearance to proceed with a Phase 1 clinical trial for its type 1 diabetes therapy, SAB-142.

SAB Biotherapeutics has appointed Dr. Jay Skyler, a renowned expert in type 1 diabetes, to its Board of Directors.

SAB Biotherapeutics announced the completion of dosing for cohort 3 in its phase one trial of SAB-142, with no instances of serum sickness observed.

SAB Biotherapeutics announced its full year 2023 financial results, highlighted by a strategic shift to focus on their SAB-142 program for Type 1 Diabetes and a significant capital raise.

SAB Biotherapeutics has entered into new executive employment agreements with its President and Chief Operating Officer, effective January 1, 2024.

SAB Biotherapeutics has appointed its Executive Chairman, Samuel J. Reich, as the new Chief Executive Officer, effective February 2, 2024, while Eddie J. Sullivan will continue as President.

SAB Biotherapeutics has entered into an agreement with Cantor Fitzgerald to potentially sell up to $20 million of its common stock through an at-the-market offering.

SAB Biotherapeutics has regained compliance with Nasdaq's minimum bid price requirement after a 1-for-10 reverse stock split.

SAB Biotherapeutics is developing a fully human antibody, SAB-142, for the prevention and treatment of Type 1 Diabetes, with promising safety and efficacy data.